During a recent Breakthrough T1D Facebook Live event, Jane Buckner, M.D., president of Benaroya Research Institute at Virginia Mason in Seattle, discussed Type 1 Diabetes TrialNet’s Hydroxychloroquine (HCQ) Prevention Study.
“I know a lot of people have questions about Hydroxychloroquine these days,” said Dr. Buckner, co-chair of the study, in acknowledgement of the controversy surrounding HCQ as a potential COVID-19 treatment. “We’re hoping that you can get an understanding for why we’ve chosen to do this clinical trial, how it works and also any concerns related to the use of the medication,” said Dr. Buckner.
During the live event, Dr. Buckner delivered a presentation covering:
- Type 1 Diabetes TrialNet
- Prevention of T1D using HCQ
- Why HCQ?
- Study details
- Status of participation
Watch the full, recorded livestream:
